Shots:
- Tarsus Pharmaceuticals has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, incl. its lead asset gildeuretinol (ALK-001), expanding Tarsus’ presence in retina care
- As per the deal, Alkeus will receive ~$450M upfront ($270M cash + $180M in Tarsus stock priced at $61.38/share), plus ~$350M in regulatory & commercial milestones, & low single-digit tiered descending royalties as a percentage of gildeuretinol net sales
- ALK-001 demonstrated a 29.5% slower annualized atrophic lesion growth rate (p<0.001) in TEASE-1 (n=50, advanced Stargardt disease) & reduced the risk of significant low-light visual acuity loss by 87% in TEASE-2 (n=79, non-atrophic Stargardt disease); P-III (NORTHSTAR) is underway, with topline data expected in H2’29
Ref: Globenewswire | Image: Alkeus | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
